From now the latest corporate news about INJEX Pharma AG only available on www.injex.com

Berlin, 21. February 2012

The District Court of Berlin Charlottenburg confirms the renaming of Paketeria AG to INJEX PHARMA/

INJEX Pharma AG has scheduled for a higher listing in the Entry Standard at the Frankfurt Stock Exchange

The renaming of Paketeria AG to INJEX PHARMA AG and additional resolutions regarding the general meeting, were published by the District Court of Berlin in Charlottenburg.

In 2012, INJEX PHARMA AG wants to secure a major worldwide role and become a prominent leader in the technology of needle free injection technology as compared to other international competitors.

The supervisory board is examining which stock exchange segment INJEX PHARMA could match. A swift change to the entry standard (Open Market) is planned, with the possibility of a transfer to a higher segment.

The company has therefore decided to remain in the stock market and to create a securities prospectus. Together with the prospectus and segment change, it allows the company to adjust the equity story and to seek strong partners on an international campaign to shape the future of the market. INJEX PHARMA AG and its shareholders will benefit from the increased transparency and improved liquidity of the securities. With the renaming and the planned segment changes, a new chapter for the company and its shareholders is unfolding.

' With the new company name INJEX Pharma AG and the planned change on a higher segment at the Frankfurt Stock Exchange we open a new chapter for the company and our shareholders. ' Our goal is to succeed in placing the equity story of INJEX PHARMA AG in a preeminent place internationally. In addition to enhancing our position on a worldwide level, we aim to provide innovation and high quality standards in a growing international market, ' stated Andy Rösch, CEO of INJEX Pharma AG .

Berlin, 29. November 2011

INJEX Pharma will start to deliver very soon the first shipment of their needle free and painless syringe INJEX30 to the Middle East to Kuwait. INJEX Pharma GmbH signed an exclusive distributor contract with Al SHAMALI GROUP Co.( BOUBYAN MEDICAL ) from Sharq-Kuwait.

In Middle East the diabetes rate is among the highest in the world. The people do not have enough exercise, people smoke, obesity is increased and nutrition sweet and unhealthy. Africa, the Middle East and India have the highest increasing prevalence worldwide.

The Al Shamali Group signed pre contracts for other countries in Middle East. The registration for the product is expected short term. The pharmaceutical division manager Dr. Wael A. Elghamri is responsible for the market introduction.

Al-Shamali Group for General Trading & Contracting was established in Kuwait City, the State of Kuwait in 1992. Over the past two decades it has grown from its humble sole focus on construction to a very diverse group of companies encompassing International Investment, Medical & Pharmaceuticals.'

Mr. Ali A. Reda, the General Manager for Al-Shamali Group Co. stated that 'INJEX is a unique instrument that will make a big difference and a relief from needle shots for Diabetic patients in Kuwait and other countries in the region. As one patient feedback after receiving and testing a starter kit sample was 'IT IS MAGIC'

Dr. Wael A. Elghamri, Pharmaceutical Division Manager (Boubyan Medical), stated: 'From our studying in our area diabetes rate is among the highest in the world, we have more than 20% of population patients with diabetes, more than 18% of them are insulin dependent. In addition we see other treatments of INJEX30 like immunization, local anesthesia and meso - therapy. So we expect very high sales at launch.'

Andy Rösch, CEO of Paketeria AG (INJEX Pharma AG): 'We are very convinced that this agreement is just the very first step with the INJEX30, made in Germany, into the Middle East Area. We have a lot of other interested companies from Middle East, who are interested to market our needle free syringe. Last week we trained directly after MEDICA our potential new partner for Saudi Arabia and we expect the contract to be signed before Christmas '

INJEX Pharma GmbH shall be merged by 100 % into Paketeria AG, listed at the Frankfurt Stock Exchange, which is the main resolution on the Annual Meeting of December 16th 2011 in Berlin. Paketeria AG will have the new company name INJEX Pharma AG.

Berlin, 25. November 2011

INJEX Pharma GmbH and GenTech Laboratories LTD signed exclusive distributor agreement for INJEX, the syringe without a needle, for India

Another important milestone for INJEX Pharma to become the worldwide market leader in 2012

INJEX Pharma based in Berlin is confirming, that the company signed an exclusive agreement for sales and marketing of the needle free drug delivery system INJEX 30. The partner is GENTECH Laboratories LTD, based in Mumbai.  Both parties agreed to keep information about the planned revenues confidential.

India is worldwide the country with the second highest population in the world with 1.2 Billion people. The gap between rich and poor people is existing, geographic size in very special, lot of people living in areas of high population density like Mumbai, New Delhi etc. Therefore the marketing activities will be very focused.

Start of sales is expected for beginning of 2012. Registration of the INJEX 30 is ongoing. Both companies believe that the INJEX-system has interesting perspectives in India, taking into consideration the strongly growing number of patients with type II diabetes.

Mr. Viraj Gandhi, Managing Director GENTECH Laboratories LTD stated: “India is the diabetes capital of the world with more than 60 million diagnosed cases as of 2010. Injex needle free delivery system will be a welcome relief to type 1 diabetes patients who have been poking themselves with a syringe for years. We are very excited about the Injex needle free syringe and its potential in India”

Gandhi and his family have been involved in the Indian pharmaceutical industry for the last 30 years. At some stage in the last few decades they have been involved in every aspect of the pharmaceutical industry value chain: manufacturing, marketing, distribution and retailing.

The INJEX System from the Berlin manufacturer INJEX Pharma GmbH offers the needle free and painless subcutaneous injection of drugs. The main user groups are diabetics, who have to inject insulin a few times every day and for doctors and for end users for injection of growth hormones, thrombosis prophylaxis, local Anesthetics for surgical and dental application, vaccinations, cancer treatment etc.

INJEX Pharma GmbH shall be merged by 100 % into Paketeria AG, listed at the Frankfurt Stock Exchange, which is the main resolution on the Annual Meeting of December 16th 2011 in Berlin. Paketeria AG will become INJEX Pharma AG.

Berlin, 24. November 2011

INJEX Pharma GmbH – Friendly Takeover and new Start as a listed company INJEX Pharma AG

With the needle free syringe INJEX, INJEX Pharma AG plans to become the first profitable company worldwide in  “Needle Free Drug Delivery“ in 2012

The Berlin based company INJEX Pharma GmbH has developed a needle free and painless syringe for injection of various medicines. After having taken several strategic measures INJEX Pharma GmbH will be merged through a capital increase with Paketeria AG, which is listed on the Frankfurt Stock Exchange. After the annual meeting of Paketeria AG on December 16th, the company will be 100 % owned by Paketeria AG, which will change the company name to INJEX Pharma AG. CEO is the founder of the INJEX business, Mr. Andy Rösch.

INJEX Pharma will begin with no debt, fully paid production assembly lines and an inventory value of 3 Million €. 2011 Sales and marketing activities have proven very successful and various exclusive distributor agreements were signed worldwide. Preliminary calculations show that the company reached the breakeven point on a monthly basis in October 2011.

“Needle Free Drug delivery Technology“ has existed for more than 25 years and it is estimated that worldwide, an investment of more than 1 Billion Euros has been spent for R & D by several international companies. Today the excitement for a “needle free future“ is still high. The market value of competitors is considerably high despite producing large losses.

INJEX Pharma has the advantage that the company has no inherited debt and a very low cost structure.  The outlook for success is excellent based on these fundamentals and the company has a clear focus for 2012: To become worldwide the first profitable company in “Needle Free Drug Delivery“ and by doing so, exciting shareholders with a new market capitalization.

August 17, 2011

Paketeria AG- Insolvency proceedings regarding the assets of the Berlin Company Paketeria AG has been repealed:

The Chief Executive Officer of Paketeria AG, Andy Rösch, received the final ruling regarding insolvency proceedings of Paketeria AG from the District Court of Charlottenburg yesterday.

The ruling reads as follows:

'The insolvency proceedings concerning the assets of the Paketeria Aktiengesellschaft, Buckower Damm 114, 12349 Berlin, represented by Andy Rösch, has been repealed by the legal confirmation of the insolvency plan according to §258 1 InsO.'

The MMB Medical Marketing Berlin GmbH submitted to the insolvency administrator an offer to creditors in summer 2010.

At the August 2010 creditors meeting, 95% of the creditors voted in favour of the of afore mentioned offer . The insolvency withdrawal is a direct result of the immediate complaint and legal appeal filed by the GenoConsult GmbH almost 1 year ago.

The Paketeria AG will work closely with the Supervisory Board regarding any and all further action to be taken. This should be achieved by integrating the business content of MMB into Paketeria AG by a planned capital increase.

The Paketeria added value concept for banks will be offered under a fair partnership as a shop in bank model.

Paketeria AG will comprehensively inform stockholders about all further steps to be taken. As a first step, the quota for creditors shall be deposited.

http://medical-marketing-berlin.com/files/Paketeria_AG_Aufhebung_Insolvenz.pdf

May 20, 2011

Medical Marketing Berlin GmbH has received a financing offer from a New York company of 5 million Euro  for the Paketeria AG

Medical Marketing Berlin GmbH has submitted an offer to the creditors of Paketeria AG in  2010, a large majority of 95% of the creditors approved the offer and the insolvency plan. In April 2011 the District Court Berlin has rejected an immediate appeal from the GenoConsult GmbH,  a consulting company of the Volksbanken, After the 4th. Of June the insolvency plan will be valid..

After the verdict , a final appeal can be filed from the GenoConsult GmbH until the 4th of June.  Such an appeal is not expected after the detailed verdict by the district court but can not be excluded. Against the GenoConsult management and the CEOs of various Volksbanks has been filed a criminal complaint..

After the insolvency  withdrawal it is planned to merge the MMB business into Paketeria AG, which is listed in the Freiverkehr at the Frankfurt Stock Exchange. To its various business areas belongs  the  "Needle Free Injex system, a device without syringe  which can inject drugs without pain.

The financial offer from New York has been transferred to MMB GmbH and Mr C, Rosenmüller, the insolvency trustee.  Mr Andy Roesch as CEO of Paketeria AG and Managing Director of MMB states that this financing offer can secure the growth of the next years.